Nektar Therapeutics (NKTR) Given Buy Rating at Jefferies Group LLC

Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reissued by Jefferies Group LLC in a research note issued to investors on Friday. They presently have a $23.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 24.86% from the stock’s current price.

A number of other equities analysts also recently issued reports on NKTR. Roth Capital set a $33.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research downgraded Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. HC Wainwright assumed coverage on Nektar Therapeutics in a research note on Monday, August 7th. They issued a “buy” rating and a $31.00 price target on the stock. Finally, Evercore ISI assumed coverage on Nektar Therapeutics in a research note on Thursday. They issued an “in-line” rating and a $20.00 price target on the stock. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Nektar Therapeutics currently has an average rating of “Buy” and a consensus price target of $26.10.

Shares of Nektar Therapeutics (NKTR) traded down 1.36% on Friday, hitting $18.17. The stock had a trading volume of 385,293 shares. The stock has a 50 day moving average of $20.53 and a 200-day moving average of $18.52. The stock’s market cap is $2.84 billion. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. The firm had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.36) earnings per share. Equities research analysts anticipate that Nektar Therapeutics will post ($0.94) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/18/nektar-therapeutics-nktr-given-buy-rating-at-jefferies-group-llc.html.

In related news, Director Lutz Lingnau sold 30,000 shares of Nektar Therapeutics stock in a transaction on Friday, July 14th. The stock was sold at an average price of $20.76, for a total transaction of $622,800.00. Following the transaction, the director now directly owns 53,450 shares in the company, valued at $1,109,622. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Ivan P. Gergel sold 54,920 shares of Nektar Therapeutics stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $21.10, for a total value of $1,158,812.00. Following the transaction, the senior vice president now owns 98,492 shares in the company, valued at $2,078,181.20. The disclosure for this sale can be found here. Insiders have sold 138,389 shares of company stock worth $2,908,403 over the last quarter. 6.10% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the stock. Flinton Capital Management LLC increased its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 460 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after buying an additional 500 shares during the last quarter. LS Investment Advisors LLC increased its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the last quarter. Finally, World Asset Management Inc increased its position in shares of Nektar Therapeutics by 5.6% in the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 539 shares during the last quarter. Institutional investors and hedge funds own 93.02% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

What are top analysts saying about Nektar Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nektar Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit